| Name | Title | Contact Details |
|---|
Palette Life Sciences is a fully integrated medical device company providing a wide range of products and services that improve quality of life of patients. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. For physicians, researchers, and inventors alike, progress begins with a natural curiosity and the drive to do more. By discovering and applying new applications of proven medicine to uncommon, or difficult to treat conditions, we can address the needs of patients often overlooked by traditional medical companies. Inspired by innovation and empathy, we see endless possibilities in expanding on proven technologies to elevate patient care. The foundation for all of our breakthrough products is Non-Animal Stabilized Hyaluronic Acid (NASHA®). NASHA has been proven safe and effective for more than two decades in over 50 million medical procedures worldwide. Barrigel® - the first and only FDA-cleared hyaluronic acid rectal spacer, minimizing the side effects of radiation therapy for prostate cancer patients. Barrigel is available in the US, Australia and Europe. Deflux® - the only FDA-approved injectable treatment for vesicoureteral reflux (VUR), a urinary defect that affects 1% of children worldwide. Deflux for VUR is available in the US, Canada, Europe, Japan, Latin America, Australia and New Zealand. Also indicated for stress urinary incontinence (SUI) in women, Deflux for SUI is available in Canada and Europe.
CoActiv Medical Business Solutions is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
brookdale medical is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eSight empowers the low vision community and advocates to #SeeNewPossibilities for people with macular degeneration, diabetic retinopathy, and 50+ other conditions that cause vision loss. Founded by electrical engineer, Conrad Lewis, who wanted to help his two legally blind sisters see, eSight has since grown to become the leading sight enhancement platform led by an executive team with the vision to do more. After seven years of research and development, the first eSight Eyewear prototype was released in 2013. Since then, the vision-enhancing electronic technology has changed the lives of thousands of people living with visual impairments and legal blindness by allowing them to retain their independence and achieve greater visual acuity at home, school, work, and play. Soon after the release of eSight 3, Time Magazine named eSight in its list of “The 25 Best Inventions in 2017” and Buzzfeed featured the device on its roster of “6 Inventions Changing British People`s Lives In 2017”. Following eSight 3, the team continued to develop its technology and, in 2020, launched its latest model — eSight 4. It was thoughtfully crafted to be wireless and hands-free allowing users to retain their mobility as well as be lightweight and streamlined for all-day comfort. The eSight 4 was later recognized as the “Best Wearable/Healthcare Hardware/Software of 2021” by the Tech Ascension Awards, which honors companies that possess the most innovative technology in their respective industry.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. As The Imaging Phenomics Company®, Median provides insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for lesion management in patient care, Lesion Management Solution (LMS) for lesion detection, measurement and reporting in clinical trials, and our imaging phenotyping system iBiopsy®, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world in bringing new and targeted treatments to patients in need with an eye on reducing overall costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris` Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.